3-(chloromethyl)-5,6-dihydroimidazo[2,1-b]thiazole hydrochloride | 72224-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并噻唑类
• 英文名称: 3-(chloromethyl)-5,6-dihydroimidazo[2,1-b]thiazole hydrochloride
• 英文别名: 3-(chloromethyl)-5H,6H-imidazo[2,1-b][1,3]thiazole hydrochloride；3-(chloromethyl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;hydrochloride
• CAS: 72224-61-4
• 化学式: C₆H₇ClN₂S*ClH
• mdl: MFCD14705616
• 分子量: 211.115
• InChiKey: BDEIPTKOCRKKBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(chloromethyl)-5,6-dihydroimidazo[2,1-b]thiazole hydrochloride 、 1,3-二异丙基-2-硫脲 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Orally Bioavailable Isothioureas Block Function of the Chemokine Receptor CXCR4 In Vitro and In Vivo

  摘要：

  The interaction of the chemokine receptor CXCR4 with its ligand CXCL12 is involved in many biological processes such as hematopoesis, migration of immune cells, as well as in cancer metastasis. CXCR4 also mediates the infection of T-cells with X4-tropic HIV functioning as a coreceptor for the viral envelope protein gp120. Here, we describe highly potent, selective CXCR4 inhibitors that block CXCR4/CXCL12 interactions in vitro and in vivo Lis well as the infection of target cells by X4-tropic HIV.

  DOI：

  10.1021/jm801065q
• 作为产物：
  描述：

  1-chloro-3-(4,5-dihydro-1H-imidazol-2-ylsulfanyl)-2-propanone hydrochloride 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以98%的产率得到3-(chloromethyl)-5,6-dihydroimidazo[2,1-b]thiazole hydrochloride
  参考文献：
  名称：

  Synthesis of 3-Chloromethyl-5,6-dihydroimidazo-[2,1-b]thiazole—A Convenient Synthon for the Preparation of Biologicaly Active Substances

  摘要：

  DOI：

  10.1007/s11178-005-0140-z

文献信息

• [EN] PROBES FOR IMAGING HUNTINGTIN PROTEIN<br/>[FR] SONDES D'IMAGERIE DE LA PROTÉINE HUNTINGTINE
  申请人：CHDI FOUNDATION INC

  公开号：WO2016033440A1

  公开（公告）日：2016-03-03

  Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use. Formula (I)

  提供了包含化合物I式或其药用可接受盐的成像剂，以及它们的使用方法。式(I)
• [EN] IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZOLINE UTILISÉS EN TANT QUE MODULATEURS DE CXCR4
  申请人：UNIV PARIS

  公开号：WO2020201096A1

  公开（公告）日：2020-10-08

  The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., lupus erythematosus, dermatomyositis or rheumatoid arthritis.

  本发明提供了化合物的新结构（I）及含有这些化合物的药物组合物。式（I）化合物可以作为CXCR4调节剂，特异性靶向CXCR4小口袋，并且进一步发现能够抑制免疫细胞中炎症细胞因子的产生，使得这些化合物在治疗中具有极大的优势，特别适用于治疗或预防炎症性疾病、自身免疫性疾病、自身炎症性疾病或干扰素病，例如红斑狼疮、皮肌炎或类风湿性关节炎。
• [EN] CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS<br/>[FR] DÉRIVÉS D'ISOTHIO-URÉE CYCLIQUES UTILISÉS COMME MODULATEURS DU CXCR4
  申请人：ERMIUM THERAPEUTICS

  公开号：WO2022064075A1

  公开（公告）日：2022-03-31

  The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., systemic lupus erythematosus, dermatomyositis or rheumatoid arthritis.

  本发明提供了式（I）的新化合物和含有这些化合物的药物组合物。式（I）的化合物可以作为CXCR4调节剂，特异性靶向CXCR4小口袋，并且已经发现它们抑制免疫细胞中炎性细胞因子的产生，这使得这些化合物在治疗中具有极大的优势，特别是在治疗或预防炎症性疾病、自身免疫性疾病、自身炎症性疾病或干扰素病中，例如系统性红斑狼疮、皮肌炎或类风湿性关节炎。
• Novel amide derivatives and medicinal use thereof ugs
  申请人：——

  公开号：US20040138223A1

  公开（公告）日：2004-07-15

  The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action 1 wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

  本发明涉及一种式（1）的酰胺衍生物，具有C5a受体拮抗作用，其中每个符号如规范中所定义。上述酰胺衍生物及其光学活性形式和药学上可接受的盐被认为是治疗或预防因C5a引起的炎症引起的疾病或综合症的药物，如自身免疫性疾病，如风湿病，系统性红斑狼疮等，败血症，成人呼吸窘迫综合症，慢性阻塞性肺疾病，哮喘等过敏性疾病，动脉粥样硬化，心脏梗死，脑梗死，牛皮癣，老年痴呆症和严重器官损伤（如肺炎，肾炎，肝炎，胰腺炎等）由于缺血再灌注，创伤，烧伤，手术入侵等引起的白细胞激活。此外，它们对通过C5a受体侵入的细菌和病毒引起的传染病也有用作治疗或预防剂。
• Thiazoline derivative and use of the same
  申请人：Kubo Keiji

  公开号：US20070010528A1

  公开（公告）日：2007-01-11

  A thiazoline derivative represented by Formula (I): wherein R is a cyclic hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; X is a bond or a divalent chain hydrocarbon group which may be substituted; X′ is a bond or —N(R 5 )—; Y is a divalent hydrocarbon group which may be substituted; Y′ is a bond or —C(═O)—; ring A is a nitrogen-containing heterocycle which may be substituted; Z 1 and Z 3 are each independently a bond or a divalent chain hydrocarbon group which may be substituted; Z 2 is a bond or —N(R 6 )—; and B is a group represented by the formula: which is useful as a therapeutic drug for thrombosis, is provided.

  提供一种由式（I）表示的噻唑啉衍生物：其中R是环烃基，可以被取代，或者是可以被取代的杂环基; X是键或二价链烃基，可以被取代; X'是键或-N(R5)-; Y是二价烃基，可以被取代; Y'是键或-C(═O)-; 环A是含氮杂环，可以被取代; Z1和Z3各自独立地是键或二价链烃基，可以被取代; Z2是键或-N(R6)-; B是下式表示的基团：该化合物可用作治疗血栓症的药物。